RTP Mobile Logo
Select Publications

Jeremy Abramson, MD

Abramson JS et al. Two-year follow-up of TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphomas (LBCL). ASH 2021;Abstract 2840.

Neelapu SS et al. Long-term follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). ASH 2021;Abstract 93.

Schuster SJ et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22(10):1403-15. Abstract

Martin Dreyling, MD, PhD

Hermine O et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A long-term follow-up of the randomized, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. ASH 2021;Abstract 380.

Di M et al. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: A population-based analysis. ASH 2021;Abstract 182.

Mehta A et al. Efficacy and safety of parsaclisib in patients with relapsed or refractory mantle cell lymphoma not previously treated with a BTK inhibitor: Primary analysis from a phase 2 study (CITADEL-205). ASH 2021;Abstract 382.

Ann S LaCasce, MD, MMSc

Advani RH et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 2021;138(6):427-38. Abstract

Kumar A et al. Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J Clin Oncol 2021;39(20):2257-65. Abstract

Kuruvilla J et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22(4):512-24. Abstract

Loretta J Nastoupil, MD

Budde LE et al. Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a phase I/II study. ASH 2021;Abstract 127.

Canales Albendea MA et al. Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study. ASCO 2021;Abstract 7545.

Morschhauser F et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21(11):1433-42. Abstract

Gilles Salles, MD, PhD

Bellada D et al. First-Mind: Primary analysis from a phase Ib, open-label, randomized study to assess safety of tafasitamab or tafasitamab + lenalidomide in addition to R‑CHOP in patients with newly diagnosed diffuse large B-cell lymphoma. ASH 2021;Abstract 3556.

Duell J et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021;106(9):2417-36. Abstract

Sehn LH et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort. Blood Adv 2021;[Online ahead of print]. Abstract